In this randomized, placebo controlled trial, patients on hemodialysis with moderate-to-severe secondary hyperparathyroidism were randomized to receive either cinacalcet or placebo. No difference was seen in the primary composite end point (time until death, myocardial infarction, hospitalization for unstable angina, heart failure, or a peripheral vascular event) between cinacalcet (48.2%) versus placebo (49.2%) HR 0.93; 95% CI, 0.85 to 1.02; P=0.11. Hypocalcemia and gastrointestinal adverse events were more common in patients on active treatment.
- Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75Years: A Randomized Clinical Trial
- Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
- Survival advantage of hemodialysis relative to peritoneal dialysis in patients with end-stage renal disease and congestive heart failure